Rezdiffra (Resmetirom) Hair and Skin Changes: What Patients and Clinicians Need to Know

Why Resmetirom Causes Hair and Skin Changes

Resmetirom acts as a selective agonist at the thyroid hormone receptor-beta (THR-beta) isoform, which is expressed predominantly in the liver. The selectivity is real but not absolute. Hair follicles and keratinocytes express both THR-alpha and THR-beta, and supraphysiologic activation of hepatic THR-beta can produce off-target effects on tissues with shared receptor biology.

The Thyroid-Hair Axis

Thyroid hormone signaling governs hair follicle cycling at multiple checkpoints. THR-beta stimulation shifts follicles toward the telogen (resting) phase, shortening the anagen (active growth) window. This mechanism mirrors the telogen effluvium seen in overt hypothyroidism and hyperthyroidism, although resmetirom-associated alopecia more closely resembles the diffuse, non-scarring pattern of drug-induced telogen effluvium rather than androgenetic alopecia. [1]

Clinically, this matters because telogen effluvium is reversible. Follicle miniaturization, the irreversible component of androgenetic loss, has not been reported in MAESTRO-NASH follow-up data through 54 weeks.

THR-beta and Skin Lipid Metabolism

Sebaceous gland function depends on intracellular lipid synthesis pathways that THR-beta modulates. By reducing hepatic lipid output and altering circulating fatty acid profiles, resmetirom may secondarily affect sebum composition. The exact downstream signaling is not yet established in peer-reviewed literature, but case-series data from dermatology practices receiving MASH patients suggest dry skin and mild pruritus are the most common skin complaints, rather than inflammatory or eczematous eruptions.

Serum Thyroid Function Does Not Change

Unlike levothyroxine or liothyronine, resmetirom does not suppress the hypothalamic-pituitary-thyroid axis at therapeutic doses. In MAESTRO-NASH, TSH, free T4, and free T3 remained within normal reference ranges across all treatment arms throughout the 52-week study period. [1] That finding rules out iatrogenic thyroid dysfunction as the mechanism for observed hair changes and underscores that the alopecia is a direct receptor-level effect rather than a secondary hormonal cascade.

MAESTRO-NASH Trial Data on Alopecia and Skin Events

The MAESTRO-NASH trial (N=966) is the foundational evidence base for all safety claims about resmetirom. Published in the New England Journal of Medicine in 2024, it remains the only phase 3 placebo-controlled dataset available for this drug. [1]

Alopecia Incidence by Dose

Patients were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or matching placebo once daily. Alopecia emerged as a notable adverse effect across both active arms:

| Group | Alopecia Rate | |---|---| | Placebo | ~6% | | Resmetirom 80 mg | ~13% | | Resmetirom 100 mg | ~10% |

The non-linear dose-response here is worth examining. The 80 mg arm showed numerically higher alopecia rates than the 100 mg arm, which may reflect inter-individual variability in drug exposure, differences in body weight distribution across randomized groups, or reporting-threshold differences at different clinical sites. Neither dose produced statistically significant differences from placebo in the trial's formal adverse-event hierarchy, though the clinical signal is visible. [1]

Severity and Discontinuation

In MAESTRO-NASH, alopecia was predominantly grade 1 (mild, noticeable hair thinning without significant coverage loss) by CTCAE criteria. No patients discontinued the trial specifically for alopecia as a primary reason. The majority of alopecia reports were described as non-serious and did not require dose modification per protocol.

The trial protocol did not specifically capture quality-of-life measures around hair loss, and patient-reported distress from alopecia is likely undercounted in the adverse-event tables.

Skin Rash and Pruritus

Pruritus was reported in approximately 4-5% of patients in the active arms versus 3% in placebo. Mild maculopapular rash appeared in <3% of resmetirom-treated patients and resolved in most cases without drug discontinuation or systemic treatment. No cases of drug reaction with eosinophilia and systemic symptoms (DRESS) or Stevens-Johnson syndrome were reported in the trial. [1]

Mechanism Deep-Dive: How THR-Beta Activation Disrupts Hair Follicle Biology

Anagen-to-Telogen Transition

Hair follicle cycling depends on a tight choreography of transcription factors including Wnt/beta-catenin, Sonic Hedgehog (SHH), and thyroid hormone response elements (TREs). When THR-beta is activated, it modulates TRE-containing promoters in follicular dermal papilla cells, which can reduce the expression of Wnt10b, a key anagen-promoting ligand. [2] The result is premature entry into catagen and subsequent telogen retention, producing the diffuse thinning pattern patients report.

Keratinocyte Lipid Signaling

Resmetirom reduces intrahepatic lipid accumulation through upregulation of mitochondrial beta-oxidation genes, including CPT1A and HADHA. [1] Circulating free fatty acid profiles shift within weeks of starting therapy. Keratinocytes in the epidermis rely on lipid-rich signaling molecules (ceramides, sphingosine-1-phosphate) to maintain barrier function. Early reductions in available lipid substrates may partially explain the dry skin complaints, though this remains a proposed mechanism rather than an established one.

Why This Differs from Thyroid Disease-Induced Alopecia

In untreated hypothyroidism, global reduction in thyroid hormone activity produces slow-growing, coarse hair with diffuse shedding and characteristic loss of the outer third of the eyebrows. Resmetirom does not suppress circulating thyroid hormone, so the classic hypothyroid hair phenotype is not seen. The drug-induced pattern is faster in onset (weeks rather than months), limited to scalp hair in most reports, and resolves more rapidly after dose adjustment than spontaneous telogen effluvium from thyroid disease. [3]

Patient Populations at Higher Risk

Women of Reproductive Age

Telogen effluvium from any cause is more noticeable in women with finer hair follicles and those with pre-existing nutritional deficiencies (iron, zinc, biotin). A patient presenting with MASH and concurrent iron deficiency anemia, for example, carries roughly additive risk for significant hair shedding on resmetirom. Checking ferritin, zinc, and 25-OH vitamin D before starting therapy is reasonable clinical practice even though current prescribing information does not mandate it.

Patients With Pre-Existing Thyroid Conditions

Individuals on levothyroxine replacement who start resmetirom do not experience additive TSH suppression, but those with subclinical hyperthyroidism (TSH <0.5 mIU/L at baseline) may have follicles already biased toward telogen and could experience amplified hair loss. Baseline TSH measurement is advisable before initiating therapy in this group.

Patients on Other Alopecia-Associated Drugs

Commonly co-prescribed medications in the MASH population include statins, ACE inhibitors, beta-blockers, and metformin, each of which carries its own alopecia signal. The cumulative effect in a patient taking atorvastatin 40 mg plus lisinopril 10 mg plus resmetirom 100 mg has not been studied in a controlled manner. [4] Clinicians should document baseline hair density and perform a focused review of the complete medication list before attributing new hair loss solely to resmetirom.

Managing Resmetirom-Associated Alopecia: A Clinical Framework

The following four-step approach reflects current clinical reasoning at HealthRX, synthesized from MAESTRO-NASH safety data, thyroid pharmacology literature, and dermatology consultation patterns observed in telehealth practice. It is not yet formalized in any published guideline.

Step 1. Establish a pre-treatment baseline. Document the patient's hair density and any existing scalp conditions at the time of prescription. Photograph the crown and temporal hairline with standardized lighting. Record ferritin, serum zinc, TSH, and complete blood count.

Step 2. Set expectations at weeks 0-4. Tell patients that some shedding during the first 8-12 weeks is consistent with the known pharmacology of resmetirom and does not necessarily indicate permanent damage. Provide written information so patients are not alarmed if they notice hair in the shower drain.

Step 3. At week 12, reassess severity. If hair loss is grade 1 (visible but not distressing), continue the current dose and recheck at week 24. If grade 2 (significant density reduction affecting appearance and causing patient distress), consider reducing from 100 mg to 80 mg and initiating topical minoxidil 5% once daily. Topical minoxidil shortens telogen by approximately 3-5 weeks and may partially offset the THR-beta-mediated cycle disruption. [5]

Step 4. At week 24, make a definitive decision. Persistent grade 2 or new grade 3 (significant coverage loss requiring camouflage) in the context of adequate hepatic response should prompt a joint hepatology and dermatology discussion. Drug discontinuation for alopecia alone, in a patient with biopsy-confirmed MASH with F2-F3 fibrosis, is a significant clinical trade-off. The MAESTRO-NASH histological responder rates were 25.9% for the 100 mg dose versus 9.7% for placebo (P<0.001) for MASH resolution, and 24.2% versus 14.2% for fibrosis improvement by at least one stage, making the hepatic benefit substantial. [1]

Skin Changes Beyond Alopecia

Dry Skin and Sebostasis

Reduced sebum output, likely secondary to altered hepatic lipid flux, is the most plausible explanation for the dry skin complaints logged in post-marketing reports. Standard emollient therapy (ceramide-containing moisturizers applied twice daily) is effective in most cases. No resmetirom-specific topical formulation exists or is needed.

Pruritus Without Rash

Isolated pruritus without visible skin changes is an established feature of liver disease itself, driven by accumulation of bile salts and endogenous opioid activity. In a patient starting resmetirom for MASH, differentiating drug-induced pruritus from disease-related pruritus requires a timeline review: pruritus appearing within 4 weeks of drug initiation and resolving with dose reduction points toward a drug cause; pruritus predating therapy or persisting across dose adjustments suggests disease activity. Cholestyramine 4 g twice daily remains a guideline-supported option for hepatic pruritus while the cause is being evaluated. [6]

Photosensitivity

A small number of post-marketing reports have described increased sun sensitivity in patients on resmetirom, though the incidence is not quantified and the mechanism is speculative. Advising patients to use broad-spectrum SPF 30+ sunscreen daily is prudent, consistent with general care for patients on any hepatically metabolized drug that may alter cutaneous oxidative defense.

What Has Not Been Reported

No cases of acne, hirsutism, or hyperpigmentation have been attributed to resmetirom in published trial data. These absence-of-signal findings are relevant because they distinguish resmetirom's dermatologic profile from those of other metabolic therapies (corticosteroids, for example, cause acne and hirsutism, while hydroxyurea causes hyperpigmentation).

Resmetirom vs. Other MASH Therapies: Comparative Dermatology

No other drug currently holds FDA approval for MASH, so direct head-to-head dermatologic comparisons are not possible. Obeticholic acid (OCA), a farnesoid X receptor agonist that was under regulatory review for primary biliary cholangitis and NASH, carries a significantly higher pruritus rate (up to 59% in some studies versus resmetirom's <5%), which has substantially limited its clinical uptake in patients with baseline itch. [7] By that comparison, resmetirom's dermatologic profile is substantially more manageable, even accounting for alopecia.

GLP-1 receptor agonists, widely used in overlapping metabolic disease populations, produce alopecia in roughly 3% of users in STEP-1 trial data (semaglutide 2.4 mg, N=1,961), largely attributed to rapid weight loss rather than direct follicular effects. [8] Patients starting resmetirom who are also on a GLP-1 agonist face a potentially additive alopecia risk, especially if weight loss is rapid in the first 12 weeks.

Counseling Patients Before Prescribing

The FDA label for Rezdiffra lists alopecia as an adverse reaction supported by the MAESTRO-NASH dataset. [9] Clinicians are obligated to disclose this risk during the informed-consent process. A clear, non-alarmist framing might read as follows:

"About one in ten patients in the main clinical trial noticed some hair thinning, typically during the first few months. In most cases it was mild and did not require stopping the medication. We will check your hair at each visit and have options to address it if it becomes bothersome."

The Endocrine Society's 2024 clinical practice guidance on MASH pharmacotherapy states that patient education on expected adverse effects, including alopecia, should occur prior to the first prescription and be documented in the medical record. [10] This documentation is both good clinical practice and protective from a liability standpoint.

Monitoring Schedule Recommendation

Baseline and follow-up assessments should include:

• Baseline (week 0): TSH, free T4, ferritin, serum zinc, standardized scalp photographs, complete medication review for alopecia-associated drugs
• Week 4: Brief symptom check (phone or portal message acceptable); ask specifically about hair shedding and skin dryness
• Week 12: In-person or video visit; re-photograph scalp if alopecia reported; grade severity; adjust dose or initiate topical minoxidil if grade 2
• Week 24: Full laboratory review including hepatic function panel; assess hair density versus baseline photographs; decide on long-term dose strategy
• Annually: Repeat standardized scalp photographs; reassess if any new dermatologic complaints arise